Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction

Yufu Zhu, Xuefeng Zhang, Jiaqi Jin, Xiaoqian Wang, Yang Liu, Jian Gao, Diancheng Hang, Lin Fang, Hengzhu Zhang, Hongmei LiuExperimental 2025 · DOI

TL;DR

Researchers have engineered an oncolytic virus (OV) coated with anti-PD-1 antibodies and alendronate. This "dressed" virus effectively targets glioblastoma by simultaneously killing cancer cells, boosting T cell activity, and reducing immunosuppressive tumor-associated macrophages, leading to a robust anti-tumor response.

What Problem Does This Paper Address?

Glioblastoma (GBM) is a highly aggressive and deadly brain cancer with a poor prognosis, largely due to its resistance to conventional therapies and its highly immunosuppressive tumor microenvironment. While oncolytic viruses (OVs) show promise by selectively killing cancer cells and stimulating an anti-tumor immune response, their efficacy is often hampered by challenges like rapid clearance by the host immune system, the presence of immunosuppressive cells (like tumor-associated macrophages or TAMs), and T cell dysfunction. Specifically, T cells, crucial for fighting cancer, can become "exhausted" due to the PD-1/PD-L1 pathway, and TAMs can engulf OVs, reducing their effectiveness. This paper aims to overcome these limitations by developing a multi-pronged therapeutic strategy.

Methods

The core innovation is the development of a "dressed" oncolytic virus, termed PD-1/Al@OV. This involves coating OVs with a ROS (reactive oxygen species)-responsive crosslinker, anti-PD-1 antibodies, and alendronate.

Here's a breakdown of the key techniques:

  • OV Engineering: A recombinant adenovirus (Ad5 backbone with Ad35 fiber) was used as the base OV.
  • Coating Mechanism: A ROS-responsive crosslinker was synthesized. This crosslinker, along with acylated alendronate and acylated anti-PD-1 antibodies, was polymerized onto the surface of the OVs. This polymerization was achieved through a free-radical polymerization reaction, leveraging the negative charge of OVs and the positive charge of an APM monomer.
  • Drug Release: The ROS-responsive nature of the crosslinker is key. In the high ROS environment characteristic of tumors, the coating is designed to disassemble, releasing the anti-PD-1 antibodies and alendronate.
  • In Vitro Assays:
    • Infection Capacity: Assessed by measuring viral gene expression (e.g., Ad5, EGFP) in infected glioma cells using Western blot and fluorescence microscopy.
  • Cytotoxicity: Evaluated using CCK-8 assays to measure cell viability after treatment with OVs and PD-1/Al@OV on various cancer and normal cell lines.
  • Apoptosis and Proliferation: Assessed using Annexin V-FITC/PI staining and flow cytometry for apoptosis, and EdU incorporation assays for proliferation.
  • TAM Depletion: Investigated using CCK-8 assays on Raw264.7 cells (a macrophage cell line) treated with alendronate and PD-1/Al@OV.
  • In Vivo Studies:
    • Orthotopic Tumor Models: Established in immunocompetent C57BL/6J mice (GL261 glioma) and immunodeficient BALB/c nude mice (U87 glioma).
  • Bioluminescence Imaging (BLI): Used to monitor tumor growth and viral replication (using engineered viruses with luciferase or DsRed genes).
  • Histopathology: H&E staining was performed on brain tumor tissues to assess tumor burden.
  • Immunohistochemistry (IHC) and Flow Cytometry (FCAS): Used to analyze immune cell infiltration (CD3, CD8, F4/80, FOXP3) and TAM populations in tumor tissues.
  • Cytokine Analysis: ELISA was used to measure levels of IL-1β, IL-6, and IFN-γ in tumor tissues.
  • Survival Analysis: Kaplan-Meier curves were used to assess the survival rates of treated mice.
  • Biodistribution and Toxicity: IVIS imaging was used to track virus distribution in organs, and biochemical tests (ALT, AST, BUN, CREA) were performed to assess systemic toxicity.

Datasets

  • TCGA Database: Used for analyzing CD46 expression in glioma patients and its correlation with prognosis.
  • Gene Expression Omnibus (GEO): Specifically, the GSE113510 dataset was used for gene expression and clinical data, and GSE131928 for single-cell RNA-seq data.

Key Insights and Ideas

  • Targeting Multiple Pathways Simultaneously: The most significant insight is the development of a single therapeutic agent that simultaneously addresses multiple critical barriers to effective GBM immunotherapy: direct tumor killing (OV), T cell activation (anti-PD-1), and reduction of immunosuppressive TAMs (alendronate).
  • ROS-Responsive Release: The clever use of a ROS-responsive crosslinker ensures that the therapeutic payloads (anti-PD-1 and alendronate) are released specifically within the tumor microenvironment, minimizing off-target effects.
  • Synergistic Immune Modulation: The combination of anti-PD-1 and alendronate with OVs appears to create a synergistic effect, transforming the "cold" GBM tumor microenvironment into a "hot" one, more conducive to immune attack.
  • Importance of Immune Competence: The study highlights the critical role of an intact immune system for the efficacy of this combined therapy, as demonstrated by the reduced effectiveness in immunodeficient mice.

Key Results

  • Enhanced Anti-Tumor Efficacy: PD-1/Al@OV treatment led to significant tumor suppression and prolonged survival in both U87 and GL261 glioma models compared to PBS, OV, or single-drug treatments.
  • Improved T Cell Infiltration: In immunocompetent mice, PD-1/Al@OV treatment significantly increased the infiltration of CD3+ and CD8+ T cells into the tumor microenvironment.
  • TAM Depletion: Alendronate, delivered via the PD-1/Al@OV, effectively reduced the population of TAMs (F4/80+ cells) in the tumor.
  • Modulation of Cytokine Profile: PD-1/Al@OV treatment led to a significant reduction in immunosuppressive cytokines (IL-1β, IL-6) and an increase in the pro-inflammatory cytokine IFN-γ.
  • Reduced Treg Cells: The treatment also resulted in a significant decrease in regulatory T cells (FOXP3+ cells), further promoting an anti-tumor immune response.
  • Safety Profile: The engineered virus showed no significant toxic effects on normal tissues or systemic organs.
  • Viral Persistence: PD-1/Al@OV demonstrated prolonged viral presence in tumor tissues compared to naked OVs.

Limitations and Future Work

  • Immunodeficient Model Limitations: The study acknowledges that in immunodeficient BALB/c nude mice, the therapeutic benefit of PD-1/Al@OV was not significantly different from naked OVs, underscoring the crucial role of T cells. This suggests that future studies should focus on immunocompetent models to fully assess the immune-modulatory effects.
  • Further Exploration of Viral Proliferation: The authors plan to investigate the proliferation of the virus under encapsulated conditions in more detail, including observing viral reproduction, measuring viral titers, and monitoring viral protein expression.
  • Animal Model Selection: The study suggests exploring appropriate animal models to better understand the distribution and load of the virus in tissues.
  • Optimization and Application: The research aims to optimize the structure and function of the virus under encapsulated conditions and explore its potential for gene delivery systems and new anti-tumor therapeutic drugs.

Summary updated

Abstract

This approach effectively improved the immunosuppressive microenvironment of glioblastoma and achieved a robust anti-tumor effect. Consequently, this study presents a novel strategy for immune combination therapy and the improvement of the glioblastoma immune microenvironment, thereby offering new prospects for the clinical application of oncolytic viruses.
BibTeX
@inproceedings{zhu2025engineered,
  author = {Yufu Zhu and Xuefeng Zhang and Jiaqi Jin and Xiaoqian Wang and Yang Liu and Jian Gao and Diancheng Hang and Lin Fang and Hengzhu Zhang and Hongmei Liu},
  title = {{Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction}},
  booktitle = {Experimental},
  year = {2025},
  doi = {10.1186/s40164-025-00611-0},
}
Figure